SubsidieMeestersIntraVenous Immune Boost
HEPHAISTOS-Pharma's ONCO-Boost is a groundbreaking intravenous TLR4 immunostimulant aimed at treating metastatic cancers, potentially curing 10x more patients than current therapies.
Projectdetails
Introduction
What if we could finally treat metastatic patients and uncurable cancers like sarcomas? HEPHAISTOS-Pharma developed ONCO-Boost, the first-in-class intravenous TLR4 immunostimulant that will be a game changer in immunotherapy.
Innovation and Development
This innovation was discovered after 40 years of research from a woman entrepreneur who developed a mature, scalable, disruptive, and eco-friendly platform. ONCO-Boost can cure hard-to-treat cancers as a stand-alone treatment but can also increase the efficacy of existing treatments.
Treatment Administration
Our cure is injected intravenously, and this changes everything. We can offer therapeutic options for patients with metastatic cancers and hardly accessible tumors. As such, ONCO-Boost can cure 10x more patients than competitors, all limited to intratumoral injection.
Ambition and Market Position
HEPHAISTOS' ambition is to become the European leader in immunostimulants, with a platform able to supply the market with large quantities of drugs, able to save millions of patients each year.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.999 |
| Totale projectbegroting | € 6.910.955 |
Tijdlijn
| Startdatum | 1-5-2024 |
| Einddatum | 28-2-2026 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- HEPHAISTOS-PHARMApenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
IOO: a novel assay to predict patient response to immune checkpoint inhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-oncology.The project aims to enhance cancer immunotherapy efficacy by developing a validated biomarker assay to predict patient responses, potentially doubling survival rates for lethal tumors. | EIC Accelerator | € 2.496.112 | 2024 | Details |
Development of a cell immunotherapy targeting non-conventional tumor antigens in ovarian cancerErVaccine aims to develop TCR-OV1, a novel TCR-T cell therapy targeting cancer-specific antigens to improve early detection and treatment outcomes for ovarian cancer patients. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Targeting Cancer with ERV VaccinesInProTher is developing BreakImmune, an immunotherapy targeting HERVs to create a cancer vaccine (IPT001) that enhances immune responses against solid tumors. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineeringThe project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer. | EIC Accelerator | € 2.434.790 | 2025 | Details |
A disruptive hypoxia activated prodrug for the treatment of resistant cancers: an AI-driven approachTUMAGOSTIC aims to advance CP-506, a targeted Hypoxia Activated Prodrug, through clinical trials to improve cancer treatment efficacy and patient outcomes, with commercialization potential exceeding €450M. | EIC Accelerator | € 2.462.533 | 2024 | Details |
IOO: a novel assay to predict patient response to immune checkpoint inhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-oncology.
The project aims to enhance cancer immunotherapy efficacy by developing a validated biomarker assay to predict patient responses, potentially doubling survival rates for lethal tumors.
Development of a cell immunotherapy targeting non-conventional tumor antigens in ovarian cancer
ErVaccine aims to develop TCR-OV1, a novel TCR-T cell therapy targeting cancer-specific antigens to improve early detection and treatment outcomes for ovarian cancer patients.
Targeting Cancer with ERV Vaccines
InProTher is developing BreakImmune, an immunotherapy targeting HERVs to create a cancer vaccine (IPT001) that enhances immune responses against solid tumors.
Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineering
The project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer.
A disruptive hypoxia activated prodrug for the treatment of resistant cancers: an AI-driven approach
TUMAGOSTIC aims to advance CP-506, a targeted Hypoxia Activated Prodrug, through clinical trials to improve cancer treatment efficacy and patient outcomes, with commercialization potential exceeding €450M.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Live biotherapeutics to potentiate cancer immunotherapyThe project aims to enhance immunotherapy efficacy by using engineered live biotherapeutics to normalize tumor stiffness and improve blood flow in colorectal and breast cancer models. | ERC Proof of... | € 150.000 | 2023 | Details |
Synergistic Antitumor Activity of Microbiome and OMV-based in situ VaccinationThe project aims to enhance immunotherapy by combining intratumoral injection of engineered bacterial OMVs with oral Bifidobacterium to boost anti-tumor immunity and improve treatment efficacy. | ERC Proof of... | € 150.000 | 2023 | Details |
Treating Liver MetastasisThis project aims to enhance immunotherapy for colorectal liver metastases by targeting innate immune responses, utilizing advanced models to identify key cellular interactions and functions. | ERC Synergy ... | € 10.180.358 | 2024 | Details |
Unlocking a T cell-mediated Immune response in therapy-challenged TumorsUnlockIT aims to develop mechanism-based combination therapies for cancer by understanding tumor-immune interactions and enhancing T cell responses in therapy-challenged tumors. | ERC Consolid... | € 2.000.000 | 2024 | Details |
Systemic delivery of oncolytic herpes simplex viruses retargeted to cancer-specific receptors. Virus optimization and business planning.This project aims to enhance systemic delivery of innovative oncolytic herpesviruses targeting HER2-positive tumors, facilitating clinical trials and commercialization to improve metastatic cancer treatment. | ERC Proof of... | € 150.000 | 2022 | Details |
Live biotherapeutics to potentiate cancer immunotherapy
The project aims to enhance immunotherapy efficacy by using engineered live biotherapeutics to normalize tumor stiffness and improve blood flow in colorectal and breast cancer models.
Synergistic Antitumor Activity of Microbiome and OMV-based in situ Vaccination
The project aims to enhance immunotherapy by combining intratumoral injection of engineered bacterial OMVs with oral Bifidobacterium to boost anti-tumor immunity and improve treatment efficacy.
Treating Liver Metastasis
This project aims to enhance immunotherapy for colorectal liver metastases by targeting innate immune responses, utilizing advanced models to identify key cellular interactions and functions.
Unlocking a T cell-mediated Immune response in therapy-challenged Tumors
UnlockIT aims to develop mechanism-based combination therapies for cancer by understanding tumor-immune interactions and enhancing T cell responses in therapy-challenged tumors.
Systemic delivery of oncolytic herpes simplex viruses retargeted to cancer-specific receptors. Virus optimization and business planning.
This project aims to enhance systemic delivery of innovative oncolytic herpesviruses targeting HER2-positive tumors, facilitating clinical trials and commercialization to improve metastatic cancer treatment.